Struggling to achieve that elusive female orgasm? Well, we might have found the nose gel for you. Yup, that's right, nose gel.
It might not sound super sexy, but Tefina has been "successfully" trialled in a recent study and could soon be available on the market.
The 'use as required' gel contains a low dose of testosterone, the male sex hormone, and researchers claim it produces no androgen-related side effects such as acne, facial and body hair growth or deepening of the voice.
The spray is designed to help women with Female Orgasmic Disorder, which is characterised by the absence, delay or reduced intensity of orgasm that causes distress or interpersonal difficulties.
The study trialled 253 women over the course of 84 days. The women were randomly placed into four groups - three of these were given a different strength Tefina dosage, while one group was given a placebo - to see whether they were more likely to orgasm.
A 0.6 mg dosage of Tefina led to an increase in the average number of orgasms during the treatment period. Numbers rose from an average of 2.3 versus 1.7 for those in the placebo arm of the trial.
"Female Orgasmic Disorder is the second most prevalent sexual disorder affecting women,'" said Dr Sheryl Kingsberg, the lead investigator clinical trial.
She adds: "Approximately one in five women report difficulty with orgasm and one quarter of these show marked distress, a key criterion in a clinical diagnosis.
"Currently, there are no approved pharmacological treatment options, leaving an unmet need that Tefina hopes to remedy."
Tom Rossi, Trimel President and CEO, added: "These results mark an important milestone in the development of Tefina.
"They provide further evidence that Tefina could represent an important treatment option for the many women who suffer from this disorder."